PT-141
Approvedaka Bremelanotide, Vyleesi
Approved libido peptide. Works on the brain, not the plumbing.
Mechanism
A melanocortin agonist that acts in the central nervous system to raise desire and arousal, a different route than the Viagra-style blood-flow drugs. It works on wanting, not just mechanics.
Regulatory & Safety Status
Approved as Vyleesi for low sexual desire (HSDD) in premenopausal women. Prescription drug. Flushing and nausea are common, fair warning.
Research
Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review
Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling
Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors
Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov
Latest bremelanotide research